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Abstract
Although aberrant expression of cytokines such as IL-1B and IFNG in blood
from psychiatric patients supports a role of inflammation in the pathogenesis of
the disease, little is known about mechanisms underlying their regulation. We
aimed to evaluate the putative role of IFNG-AS1 long non-coding RNA
(lncRNA) in controlling of IFNG locus in patients with schizophrenia (SZ) and
bipolar (BP). We analysed the expression levels of IFNG-AS1 long non-coding
RNA, and IFNG and IL-1B mRNAs in blood cells from 27 SZ- and 30 BP-
medicated patients and in 32 healthy controls. Our data showed that IFNG-AS1
expression dramatically decreased in BP and SZ patients compared with controls
and was significantly correlated with IFNG expression in patients specifically.
Transcript levels of IL-1B were also significantly reduced in BP and SZ patients
compared with controls. No significant differences in the expression of IFNG-
AS1, IFNG and IL-1B genes were found between patients with BP and SZ. Our
data shed further light on the potential role of inflammation, and more
particularly inflammatory lncRNAs, in SZ and BP diseases and their pharma-
cological treatment.
Introduction
Schizophrenia (SZ) and bipolar (BP) disorders are
clinically and aetiologically heterogeneous debilitating
chronic psychiatric diseases. Several studies have revealed
that both genetics and environmental factors are involved
in the pathogenesis of SZ and BP [1]. Despite marked
differences in the aetiology and clinical course between
BP and SZ diseases, they share common features
regarding underlying genetic loci and gene expression
changes [2, 3]. Inflammation and infections have been
implicated in the pathogenesis of SZ [4] and BP [5], and
dysregulated levels of inflammatory molecules and
cytokines were found in peripheral blood from patients
with SZ and BP [6]. IL-1b is a pro-inflammatory
cytokine secreted by a variety of cells such as peripheral
and brain macrophages (monocytes, microglial cells),
astrocytes and brain endothelial cells and is a known pro-
inflammatory mediator of inflammatory reactions of the
central nervous system (CNS) [7]. IL-1b involvement in
the pathogenesis of psychiatric disease such as SZ and BP
likely arises from its effect on the development of the
neurotransmitter systems [8, 9] and its contribution to
neuroimmune and neuroinflammatory processes, the
latter via activation of other immune cells such as
peripheral and CNS-resident macrophages and T cells,
disruption of the blood–brain barrier (BBB) and subse-
quent alteration of the brain functions [10, 11]. Another
important inflammatory mediator, which was found
dysregulated in SZ and BP [12, 13] and may affect the
immune-related pathogenesis of SZ and BP, is interferon-
gamma (IFN-c). IFN-c is a pro-inflammatory cytokine
mostly produced peripherally by pro-inflammatory Th1
T lymphocytes and NK cells but also centrally within
the CNS by neurons and glial cells [14]. In addition to
its role in microglia-mediated neuronal dysfunction [15],
IFN-c may affect the brain function by directly altering
neuronal circuits [16], synaptic plasticity [17, 18] or the
kynurenine pathway [19]. Importantly, genetic variation
of the IFNG gene has been associated with risk to
develop SZ and BP [20–22]. However, the molecular
mechanisms underlying cytokine expression involved in
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